Stock Groups

Biogen’s Alzheimer’s drug gets negative vote from EMA panel -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO: An indication marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian Snyder

(Reuters) -Biogen Inc mentioned on Wednesday a European Medicines Company panel has voted towards the advertising and marketing utility for its Alzheimer’s illness drug, sending shares of the drugmaker down 3%.

The panel, Committee for Medicinal Merchandise for Human Use, will undertake a ultimate opinion at a December assembly, the corporate mentioned.

The U.S. approval for the drug, aducanumab, has drawn criticism from scientists, who’re doubting whether or not the scientific proof proves that the therapy works.

Disclaimer: Fusion Media wish to remind you that the information contained on this web site isn’t essentially real-time nor correct. All CFDs (shares, indexes, futures) and Foreign exchange costs are usually not supplied by exchanges however relatively by market makers, and so costs will not be correct and should differ from the precise market value, that means costs are indicative and never acceptable for buying and selling functions. Subsequently Fusion Media doesn`t bear any accountability for any buying and selling losses you may incur on account of utilizing this knowledge.

Fusion Media or anybody concerned with Fusion Media won’t settle for any legal responsibility for loss or harm on account of reliance on the knowledge together with knowledge, quotes, charts and purchase/promote alerts contained inside this web site. Please be totally knowledgeable relating to the dangers and prices related to buying and selling the monetary markets, it is among the riskiest funding types doable.



[ad_2]